Testing a new treatment for pancreatic neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial is for people with high-grade pancreatic neuroendocrine tumors (a type of pancreas cancer) whose previous treatments stopped working. It tests whether a new approach can help when standard options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic neuroendocrine tumor or carcinoma.
- Your prior cancer treatment has stopped working.
- Your blood counts (neutrophils and platelets) are high enough.
- You are not currently being treated for another cancer (unless you finished treatment over 2 years ago).
- You are not pregnant or breastfeeding.
- You agree to follow the study procedures and complete the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called lurbinectedin to paclitaxel (a standard chemotherapy) works better than paclitaxel alone for small cell lung cancer that has come back after prior treatment. The goal is to see if this combination helps patients live longer and controls their cancer better.
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Hear when a new Neuroendocrine Tumor of Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.